In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadership

Set Alert for Leadership

Pfizer’s Safe House: Peter Honig Builds A Regulatory Model For The Future

In Vivo talks to Pfizer SVP for worldwide safety and regulatory Peter Honig on the challenges of establishing – and then maintaining – the confidence of a diverse array of constituencies in the safe, effective use of medicines for a $50 billion business.   

BioPharmaceutical Safety Regulation
Advertisement

Latest From Leadership

Execs On The Move, December 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Zimmer Biomet Shows How To Keep Operational Issues From Eclipsing Strategic Goals

While Zimmer Biomet's search goes on for a new CEO to replace David Dvorak, who stood down in mid-summer, analysts are pressing for a replacement in short order to put stability back into the global No.2 orthopedic device group, which has sales headwinds and ongoing implant production issues at North Campus, Warsaw, to contend with.

Orthopedics Medical Device

Execs On The Move, November 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Appointments Leadership

Execs On The Move, October 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Veteran biopharma deal-maker Mark Enyedy has a new role as CEO of ImmunoGen, currently an investor favorite – company shares are up nearly 200% this year. In this interview he discusses corporate restructuring, the evolving role of business development and making new scientific inroads against hard-to-treat cancers.

BioPharmaceutical Deals

Execs On The Move, September 2017

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

BioPharmaceutical Medical Device
See All
UsernamePublicRestriction

Register